A new formulation of Rybelsus® with increased bioavailability is available to prescribe in primary care across north central London (NCL) from 18 November 2025.

Further to the information issued on 22 October, the NCL ICB's Medicines Optimisation Team, in conjunction with the NCL Diabetes Network and system partners, has issued a detailed system-wide communication regarding the risk of medication error due to the introduction of a new formulation of Rybelsus® (oral semaglutide) with increased bioavailability.

The guidance has been developed to support prescribers and dispensers, and provides risk minimisation strategies and guidance on 
•    switching patients on the original formulation of Rybelsus® (oral semaglutide) to the new formulation in primary care
•    actions for community and hospital providers 
•    actions for pharmacies in the community and hospital.

See the Prescribing Guideline for more detail on the prescribing information for primary care. 

This item was updated on 18 November 2025 to highlight the introduction of the newly changed formulation of Rybelsus® (oral semaglutide) on that date. NCL ICS supporting information is available for prescribers.